Scarica l'app Stockscreener
259.57
1.47%
-3.86
Dopo l'orario di chiusura:
259.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LH Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Labcorp Holdings Inc Borsa (LH) Ultime notizie
Labcorp's Q4 earnings preview: What's in store for the stock? - MSN
Labcorp slips after Q4 revenue miss - MSN
Labcorp falls as 2025 revenue guidance midpoint lowered - MSN
Vanguard (LH) holds 6.20M shares, 7.52% stake disclosed in Schedule 13G - Stock Titan
Teacher Retirement System of Texas Sells 4,759 Shares of Labcorp Holdings Inc. $LH - MarketBeat
Barclays Maintains Labcorp Holdings (LH) Equal-Weight Recommendation - MSN
Universal Beteiligungs und Servicegesellschaft mbH Has $24.01 Million Stock Position in Labcorp Holdings Inc. $LH - MarketBeat
B. Metzler seel. Sohn & Co. AG Acquires 15,471 Shares of Labcorp Holdings Inc. $LH - MarketBeat
Labcorp Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Labcorp Holdings (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Labcorp Holdings (LH) Stock Movers | Labcorp Holdings Inc notches 0.3% EPS beat, solid revenueLiquidity Risk - Xã Thanh Hà
Labcorp (LH) to Release Earnings on Thursday - MarketBeat
LH Labcorp Holdings reports modest Q4 2025 EPS beat and 7.2% YoY revenue rise, shares edge lower.Trending Momentum Stocks - UBND thành phố Hải Phòng
LH (Labcorp Holdings Inc.) delivers 7.2% YoY Q4 2025 revenue growth and small EPS beat, shares edge down 0.8%. - Xã Thanh Hà
Labcorp Holdings Inc. $LH Shares Acquired by M&T Bank Corp - MarketBeat
Labcorp launches diagnostic test for ovarian cancer treatment By Investing.com - Investing.com Canada
New lab test helps doctors identify ovarian cancer patients for KEYTRUDA - Stock Titan
Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA® - Sahm
A Look At Labcorp (LH) Valuation As New Tests And AI Alzheimer’s Platform Gain Traction - Sahm
Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
All You Need to Know About Labcorp (LH) Rating Upgrade to Buy - Yahoo Finance
Labcorp Gears Up to Report Q1 Earnings: What's in Store? - Yahoo Finance
Labcorp Holdings Inc. (LH) Stock Analysis: Evaluating a 14.55% Potential Upside for Investors - DirectorsTalk Interviews
Birch Hill Investment Advisors LLC Sells 37,071 Shares of Labcorp Holdings Inc. $LH - MarketBeat
Labcorp Holdings Inc. $LH Stake Boosted by KBC Group NV - MarketBeat
Labcorp Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Illumina (ILMN), Labcorp (LH) expand precision oncology NGS collaboration - MSN
Is It Time To Reassess Labcorp (LH) After Its Recent Share Price Strength? - Sahm
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes - Sahm
Sumitomo Mitsui Trust Group Inc. Sells 28,674 Shares of Labcorp Holdings Inc. $LH - MarketBeat
Labcorp’s Rapid Fentanyl Test Clearance And What It Means For Valuation - Yahoo Finance
How Investors Are Reacting To Labcorp (LH) AI-Powered Real-World Data Push In Complex Disease Research - Yahoo Finance
Labcorp launches FDA-cleared rapid fentanyl urine test By Investing.com - Investing.com Canada
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes – Company Announcement - Financial Times
Labcorp's new 10-minute fentanyl test gives ER teams faster answers - Stock Titan
Labcorp (LH) Unveils AI-Driven Platform for Accelerating Alzheimer's Research - GuruFocus
Labcorp Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Labcorp Introduces Ai-Powered Real-World Data Platform with Aws and Datavant - marketscreener.com
Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Baird Adjusts Price Target on Labcorp Holdings to $332 From $327, Maintains Outperform Rating - marketscreener.com
Leerink Partners Adjusts Labcorp PT to $347 From $342, Maintains Outperform Rating - marketscreener.com
0.80%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):